US 12,331,127 B2
Therapeutic uses of anti-GITR antibodies
Robert Babb, River Edge, NJ (US); Drew Dudgeon, Montvale, NJ (US); Yu Huang, Ossining, NY (US); Rosalynn Molden, Shoreline, WA (US); William Olson, Yorktown Heights, NY (US); Matthew Sleeman, Yorktown Heights, NY (US); Dimitris Skokos, New York, NY (US); and Bei Wang, Hastings-on-Hudson, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Sep. 6, 2023, as Appl. No. 18/461,760.
Application 18/461,760 is a division of application No. 17/193,586, filed on Mar. 5, 2021, granted, now 11,787,867.
Claims priority of provisional application 62/986,494, filed on Mar. 6, 2020.
Prior Publication US 2024/0076396 A1, Mar. 7, 2024
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 55 Claims
OG exemplary drawing
 
27. A method for modulating anti-tumor immune response, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to glucocorticoid-induced tumor necrosis factor receptor (GITR), wherein the antibody or antigen-binding fragment thereof comprises:
(i) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:4, the HCDR2 comprises the amino acid sequence of SEQ ID NO:6, and the HCDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:36, and SEQ ID NO:42; and
(ii) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:12, the LCDR2 comprises the amino acid sequence of SEQ ID NO:14, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:16.